眼科疾患治療薬の世界市場 (2023-2030年)：適応症 (緑内障・網膜疾患)・薬剤クラス (抗炎症薬・抗感染薬) 別の規模・シェア・成長分析・予測

世界の眼科疾患治療薬の市場規模は、予測期間中は6.1%のCAGRで推移し、478億3,100万米ドルの規模に成長すると予測されています。

世界中で眼科疾患の有病率が増加し、視力ケアと治療に対する需要が高まる中、米国国立眼科研究所 (National Eye Institute) の予測によると、米国経済における視力低下と眼科疾患の年間コストは1,390億米ドルに上ると推計されています。

大手製薬会社は、網膜疾患治療のための革新的な治療法のR&Dに多大な資源を投入しています。その結果、近い将来に最先端の治療法が承認されることが期待されており、眼科疾患治療薬市場の成長を後押ししています。さらに、アジア諸国の製造業者による手頃な価格の眼科治療薬の導入がOTC治療薬の市場開拓に道を開いており、予測期間中の収益増加に貢献すると予想されています。

同市場では現在、抗炎症薬、抗感染薬、抗VEGF薬、抗緑内障薬など、さまざまな薬剤クラスが提供されています。中でも抗炎症薬は2022年に27%で最大のシェアを示し、予測期間中も支配的な地位を維持すると予想されています。

アレルギー性結膜炎や過敏性反応の急増に加え、ぶどう膜炎、嚢胞様黄斑浮腫、強膜炎などのさまざまな症状に対処するための抗炎症薬に対するニーズが高まっていることから、抗炎症薬の部門は2022年に大幅な成長を示し、当面は主導的地位を維持すると予想されています。また、アレルギー性結膜炎の有病率の上昇により、抗感染薬の部門も予測期間中に大幅な成長を遂げると予測されています。

適応症別では、糖尿病患者の世界的な増加から、網膜疾患の部門が2022年に大幅な成長を遂げました。米国疾病予防管理センター (CDC) の予測によると、糖尿病性網膜症を患う米国人は2050年までに1,460万人に増加し、2010年の770万人から大幅に急増すると予想されています。この疾患は、治療せずに放置すると永久的な視力の喪失につながることが判明しています。そのため、眼科業界は眼科治療薬の開発と製造で対応すると予測されており、さらなる市場の拡大が促される見通しです。

地域別では、需要増に対応するための流通システムの強化により、アジア太平洋地域が著しい成長を遂げており、最大のCAGRを示すと予測されています。一方、北米も市場で重要な位置付けにあり、2023年には140億米ドルの収益規模を示しています。これは主に、米国における網膜疾患の有病率の高さと、同国における強力な眼科疾患治療薬の導入に起因しています。収益規模では欧州が北米に次いで第2位に位置付けています。

主要企業

• Merck and Co., Inc.
• Pfizer, Inc.
• Novartis AG
• Allergan plc
• F. Hoffmann-La Roche AG
• Regeneron Pharmaceuticals, Inc.
• Santen Pharmaceutical Co., Ltd.
• Bayer AG
• Bausch and Lomb, Inc.

当レポートでは、世界の眼科疾患治療薬の市場を調査し、市場概要、市場への各種影響因子の分析、技術・イノベーションの動向、法規制環境、市場規模の推移・予測、各種区分・地域別の内訳、競合情勢、主要企業のプロファイルなどをまとめています。

目次

エグゼクティブサマリー

市場概要

親市場の分析

市場概要

市場規模

• 市場力学
• 促進要因
• 機会
• 抑制要因
• 課題
• SWOT分析

主要市場洞察

• 技術分析
• 価格分析
• サプライチェーン分析
• バリューチェーン分析
• 市場のエコシステム
• IP分析
• 貿易分析
• スタートアップ分析
• 原材料分析
• イノベーションマトリックス
• パイプライン製品の分析
• マクロ経済指標

COVID-19の影響

• 経済への影響- シナリオ評価
• 市場規模の修正
• 主要部門に対するCOVID-19の影響
• 企業によるCOVID-19戦略

市場力学と見通し

• 市場力学
• 促進要因
• 機会
• 抑制要因
• 課題
• 規制状況
• SWOT分析
• ポーターの分析
• 将来のディスラプションに関するSkyquestの特別な洞察

市場規模：地域別

• 北米
• 欧州
• アジア太平洋
• ラテンアメリカ
• 中東・アフリカ

主要な企業プロファイル

• 競合情勢

Ophthalmic Disease Therapeutics Market is estimated to reach USD 47.831 billion at a CAGR of 6.1% during the forecast period (2022-2028).

With the increasing prevalence of ocular diseases worldwide and a growing demand for vision care and treatment on a global scale, the National Eye Institute projects that the annual cost of vision loss and eye-related ailments to the U.S. economy amounts to a substantial $139 billion. This foreseen expansion of the global ophthalmic therapeutics market is primarily attributed to the escalating prevalence of blindness.

Prominent pharmaceutical companies are dedicating significant resources to research and develop innovative therapies for treating retinal disorders. As a result, it is expected that cutting-edge treatments will receive approval in the near future, thus propelling the growth of the ophthalmic disease therapeutics market. Furthermore, the introduction of affordable ocular drugs by local manufacturers in Asian countries has paved the way for the development of Over-the-Counter (OTC) therapeutics, which is anticipated to contribute to increased revenue in the global ophthalmic disease therapeutics market during the forecast period.

The market currently offers a range of medication classes, including anti-inflammatory, anti-infectives, anti-VEGF, anti-glaucoma, and others. Among these, anti-inflammatory medications held the largest share, accounting for 27% of ocular disease therapies in 2022, and are expected to maintain their dominant position throughout the forecast period.

Top-down and bottom-up approaches were used to estimate and validate the size of Ophthalmic Disease Therapeutics and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined by using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Ophthalmic Disease Therapeutics Market Segmental Analysis

Ophthalmic Disease Therapeutics Market is segmented based on the disease indication, drug class, and region. Based on the disease indication, the market is segmented as a glaucoma, retinal disease, dry eye disease, allergy & infection. Based on drug class, the market is segmented into anti-inflammatory, anti - infectives, anti- vegf, anti-glaucoma. Based on region, the global market segmentation spans North America, Europe, Asia-Pacific, Latin America, and MEA.

Ophthalmic Disease Therapeutics Market Analysis by Drug Class

Due to a surge in cases of allergic conjunctivitis and hypersensitivity reactions, as well as a growing need for anti-inflammatory drugs to address various conditions like uveitis, cystoid macular edema, and scleritis, the anti-inflammatory sector experienced remarkable expansion in 2022 and is expected to maintain its leading position in the foreseeable future. Nevertheless, owing to the rising prevalence of allergic conjunctivitis, the anti-infectives segment is projected to undergo substantial growth during the forecast period.

Ophthalmic Disease Therapeutics Market Analysis by Disease

Based on specific disease indications, the market is categorized into various segments, including allergies, infections, glaucoma, retinal disorders, and dry eye diseases. Notably, the retinal disorders segment experienced substantial growth in 2022, primarily attributed to a rise in diabetes cases worldwide. According to projections from the Centers for Disease Control and Prevention (CDC), the number of Americans with diabetic retinopathy is expected to increase to 14.6 million by 2050, a significant surge from 7.7 million in 2010. It has been found that this condition can lead to permanent vision loss if left untreated. Consequently, the ophthalmology industry is expected to respond by developing and manufacturing ophthalmic medications, further stimulating market expansion.

Global Ophthalmic Disease Therapeutics Market Regional Insights

The Asia Pacific market for ocular drugs is experiencing remarkable growth, driven by an enhanced distribution system to meet the increasing demand. The region is expected to have the highest Compound Annual Growth Rate (CAGR) in this sector. Meanwhile, North America holds a significant position in the ophthalmic disease therapeutics market, generating revenues of US$14 billion in 2023. This is mainly attributed to the high prevalence of retinal diseases in the United States and the introduction of potent ophthalmic disease therapeutics in the country. Europe follows North America as the second leading region in terms of revenue. Throughout the projection period, Asian countries are anticipated to witness a surge in ophthalmic disease therapies, thanks to the improved distribution network of major pharmaceutical firms and the implementation of robust government measures to prevent and control blindness.

Global Ophthalmic Disease Therapeutics Market Dynamics

Ophthalmic Disease Therapeutics Market Driver

Presence of small and mid-sized organizations to boost the market growth

Prominent players in the ophthalmic disease therapeutics industry include Allergan plc, F. Hoffmann-La Roche AG, and Regeneron Pharmaceuticals, Inc. The global market is characterized by significant fragmentation, with numerous small and mid-sized regional competitors gaining traction.

Macular degeneration, macular edema, and retinal vein occlusion are among the major ophthalmic diseases treatable with widely recognized medications such as Eylea from Regeneron Pharmaceuticals, Inc., and Lucentis from F. Hoffmann-La Roche AG.

Ophthalmic Disease Therapeutics Market Restraint

During the projected timeframe, the market growth is anticipated to be hindered due to the extended manufacturing and formulating processes of ophthalmic drugs, coupled with the accompanying side effects these drugs may induce.

Global Ophthalmic Disease Therapeutics Market Competitive Landscape

The market for ophthalmic disease therapeutics exhibits a considerable degree of fragmentation, leading to intense competition among companies. To stay ahead in this dynamic landscape, these companies are actively engaged in introducing innovative products and undertaking various initiatives to enhance customer experiences and achieve global expansion. Recognized players in the industry are diligently broadening their customer reach through diverse strategies, while simultaneously forging inventive partnerships with emerging businesses, all aimed at bolstering market dominance and overall profitability.

Top Players in the Global Opthalmic Disease Therapeutics Market

Merck and Co., Inc.

Pfizer, Inc.

Novartis AG

Allergan plc

F. Hoffmann-La Roche AG

Regeneron Pharmaceuticals, Inc.

Santen Pharmaceutical Co., Ltd.

Bayer AG

Bausch and Lomb, Inc.

Ophthalmic Disease Therapeutics Market Recent Developments

In Feb 2021, Dextenza, a product by Ocular Therapeutix was made available in the market. This product enables the course of steroid therapy possible just with a single installation of intracanalicular device.

In June 2020, the collaboration agreement between Aerie Pharmaceuticals, Inc. and DSM Biomedical, Inc. has been extended to include innovative drug delivery techniques in ophthalmology.

Key Market Trends

Global Ophthalmic Disease Therapeutics Key Market Trends

Technological progress in the field of ophthalmology has led to the creation of innovative imaging techniques and surgical instruments, enhancing the well-being of patients afflicted with eye ailments. A prime example of such progress is the adoption of femtosecond lasers in cataract surgery, which significantly enhances precision and reduces the likelihood of complications.

The realm of personalized medicine has experienced a surge in attention owing to the emergence of targeted therapies. Consequently, novel medications are being designed to cater specifically to individual patient requirements, marking a significant step forward in medical advancement.

Global Ophthalmic Disease Therapeutics Market SkyQuest Analysis

SkyQuest's ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Co-relates, and Analyses the Data collected utilizing Primary Exploratory Research backed by the robust Secondary Desk research.

Based on our comprehensive analysis, the Global Ophthalmic Disease Therapeutics report presents a detailed industry overview, emphasizing crucial elements such as key players, sources, products, and applications. The research highlights notable developments within the sector and offers valuable market trend insights and competitive landscape assessments. Additionally, the study covers various other factors that have significantly contributed to the market's growth in recent times.

Table of Contents

Executive Summary

Market overview

• Exhibit: Executive Summary - Chart on Market Overview
• Exhibit: Executive Summary - Data Table on Market Overview
• Exhibit: Executive Summary - Chart on Global Ophthalmic Disease Therapeutics Market Characteristics
• Exhibit: Executive Summary - Chart on Market by Geography
• Exhibit: Executive Summary - Chart on Market Segmentation
• Exhibit: Executive Summary - Chart on Incremental Growth
• Exhibit: Executive Summary - Data Table on Incremental Growth
• Exhibit: Executive Summary - Chart on Vendor Market Positioning

Parent Market Analysis

Market overview

Market size

• Market Dynamics
  • Exhibit: Impact analysis of DROC, 2021
• Drivers
• Opportunities
• Restraints
• Challenges
• SWOT Analysis

KEY MARKET INSIGHTS

• Technology Analysis
  • (Exhibit: Data Table: Name of technology and details)
• Pricing Analysis
  • (Exhibit: Data Table: Name of technology and pricing details)
• Supply Chain Analysis
  • (Exhibit: Detailed Supply Chain Presentation)
• Value Chain Analysis
  • (Exhibit: Detailed Value Chain Presentation)
• Ecosystem Of the Market
  • Exhibit: Parent Market Ecosystem Market Analysis
  • Exhibit: Market Characteristics of Parent Market
• IP Analysis
  • (Exhibit: Data Table: Name of product/technology, patents filed, inventor/company name, acquiring firm)
• Trade Analysis
  • (Exhibit: Data Table: Import and Export data details)
• Startup Analysis
  • (Exhibit: Data Table: Emerging startups details)
• Raw Material Analysis
  • (Exhibit: Data Table: Mapping of key raw materials)
• Innovation Matrix
  • (Exhibit: Positioning Matrix: Mapping of new and existing technologies)
• Pipeline product Analysis
  • (Exhibit: Data Table: Name of companies and pipeline products, regional mapping)
• Macroeconomic Indicators

COVID IMPACT

• Introduction
• Impact On Economy-scenario Assessment
  • Exhibit: Data on GDP - Year-over-year growth 2016-2022 (%)
• Revised Market Size
  • Exhibit: Data Table on Global Ophthalmic Disease Therapeutics Market size and forecast 2021-2027 ($ million)
• Impact Of COVID On Key Segments
  • Exhibit: Data Table on Segment Market size and forecast 2021-2027 ($ million)
• COVID Strategies By Company
  • Exhibit: Analysis on key strategies adopted by companies

MARKET DYNAMICS & OUTLOOK

• Market Dynamics
  • Exhibit: Impact analysis of DROC, 2021
• Drivers
• Opportunities
• Restraints
• Challenges
• Regulatory Landscape
  • Exhibit: Data Table on regulation from different region
• SWOT Analysis
• Porters Analysis
  • Competitive rivalry
• Exhibit: Competitive rivalry Impact of key factors, 2021
  • Threat of substitute products
• Exhibit: Threat of Substitute Products Impact of key factors, 2021
  • Bargaining power of buyers
• Exhibit: buyers bargaining power Impact of key factors, 2021
  • Threat of new entrants
• Exhibit: Threat of new entrants Impact of key factors, 2021
  • Bargaining power of suppliers
• Exhibit: Threat of suppliers bargaining power Impact of key factors, 2021
• Skyquest special insights on future disruptions
  • Political Impact
  • Economic impact
  • Social Impact
  • Technical Impact
  • Environmental Impact
  • Legal Impact

Market Size by Region

• Chart on Market share by geography 2021-2027 (%)
• Data Table on Market share by geography 2021-2027(%)
• North America
  • Chart on Market share by country 2021-2027 (%)
  • Data Table on Market share by country 2021-2027(%)
  • USA
• Exhibit: Chart on Market share 2021-2027 (%)
• Exhibit: Market size and forecast 2021-2027 ($ million)
  • Canada
• Exhibit: Chart on Market share 2021-2027 (%)
• Exhibit: Market size and forecast 2021-2027 ($ million)
• Europe
  • Chart on Market share by country 2021-2027 (%)
  • Data Table on Market share by country 2021-2027(%)
  • Germany
• Exhibit: Chart on Market share 2021-2027 (%)
• Exhibit: Market size and forecast 2021-2027 ($ million)
  • Spain
• Exhibit: Chart on Market share 2021-2027 (%)
• Exhibit: Market size and forecast 2021-2027 ($ million)
  • France
• Exhibit: Chart on Market share 2021-2027 (%)
• Exhibit: Market size and forecast 2021-2027 ($ million)
  • UK
• Exhibit: Chart on Market share 2021-2027 (%)
• Exhibit: Market size and forecast 2021-2027 ($ million)
  • Rest of Europe
• Exhibit: Chart on Market share 2021-2027 (%)
• Exhibit: Market size and forecast 2021-2027 ($ million)
• Asia Pacific
  • Chart on Market share by country 2021-2027 (%)
  • Data Table on Market share by country 2021-2027(%)
  • China
• Exhibit: Chart on Market share 2021-2027 (%)
• Exhibit: Market size and forecast 2021-2027 ($ million)
  • India
• Exhibit: Chart on Market share 2021-2027 (%)
• Exhibit: Market size and forecast 2021-2027 ($ million)
  • Japan
• Exhibit: Chart on Market share 2021-2027 (%)
• Exhibit: Market size and forecast 2021-2027 ($ million)
  • South Korea
• Exhibit: Chart on Market share 2021-2027 (%)
• Exhibit: Market size and forecast 2021-2027 ($ million)
  • Rest of Asia Pacific
• Exhibit: Chart on Market share 2021-2027 (%)
• Exhibit: Market size and forecast 2021-2027 ($ million)
• Latin America
  • Chart on Market share by country 2021-2027 (%)
  • Data Table on Market share by country 2021-2027(%)
  • Brazil
• Exhibit: Chart on Market share 2021-2027 (%)
• Exhibit: Market size and forecast 2021-2027 ($ million)
  • Rest of South America
• Exhibit: Chart on Market share 2021-2027 (%)
• Exhibit: Market size and forecast 2021-2027 ($ million)
• Middle East & Africa (MEA)
  • Chart on Market share by country 2021-2027 (%)
  • Data Table on Market share by country 2021-2027(%)
  • GCC Countries
• Exhibit: Chart on Market share 2021-2027 (%)
• Exhibit: Market size and forecast 2021-2027 ($ million)
  • South Africa
• Exhibit: Chart on Market share 2021-2027 (%)
• Exhibit: Market size and forecast 2021-2027 ($ million)
  • Rest of MEA
• Exhibit: Chart on Market share 2021-2027 (%)
• Exhibit: Market size and forecast 2021-2027 ($ million)

KEY COMPANY PROFILES

• Competitive Landscape
  • Total number of companies covered
• Exhibit: companies covered in the report, 2021
  • Top companies market positioning
• Exhibit: company positioning matrix, 2021
  • Top companies market Share
• Exhibit: Pie chart analysis on company market share, 2021(%)